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Sensorineural deafness and retinitis pigmentosa (RP) are the hallmarks of Usher syndrome (USH) but are also
prominent features in peroxisomal biogenesis defects (PBDs); both are autosomal recessively inherited. The firstborn
son of unrelated parents, who both had sensorineural deafness and RP diagnosed as USH, presented with senso-
rineural deafness, RP, dysmorphism, developmental delay, hepatomegaly, and hypsarrhythmia and died at age 17
mo. The infant was shown to have a PBD, on the basis of elevated plasma levels of very-long- and branched-chain
fatty acids (VLCFAs and BCFAs), deficiency of multiple peroxisomal functions in fibroblasts, and complete absence
of peroxisomes in fibroblasts and liver. Surprisingly, both parents had elevated plasma levels of VLCFAs and BCFAs.
Fibroblast studies confirmed that both parents had a PBD. The parents’ milder phenotypes correlated with relatively
mild peroxisomal biochemical dysfunction and with catalase immunofluorescence microscopy demonstrating mo-
saicism and temperature sensitivity in fibroblasts. The infant and both of his parents belonged to complementation
group C. PEX6 gene sequencing revealed mutations on both alleles, in the infant and in his parents. This unique
family is the first report of a PBD with which the parents are themselves affected individuals rather than asymp-
tomatic carriers. Because of considerable overlap between USH and milder PBD phenotypes, individuals suspected
to have USH should be screened for peroxisomal dysfunction.
Peroxisomal biogenesis disorders (PBDs [MIM601539])
are caused by mutations in PEX genes encoding peroxins
required for targeting of peroxisomal proteins from the
cytosol to the peroxisome and for their subsequent im-
portation into the organelle (Gould and Valle 2000).
These autosomal recessively inherited disorders are char-
acterized by absence of morphologically identifiable per-
oxisomes and deficiency of multiple peroxisomal meta-
bolic functions. PBDs are multisystem disorders mani-
festing with craniofacial dysmorphism, hypotonicity, sei-
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zures, psychomotor retardation, vision and hearing im-
pairment, and skeletal, renal, hepatic, and gastrointes-
tinal disease. Their clinical spectrum ranges from the
full-blown phenotype of Zellweger syndrome (ZS [MIM
214100]), which is fatal in infancy; through the in-
termediate form, adrenoleukodystrophy (NALD [MIM
202370]), which has predominant neurological features
and survival for 1 or several years; to the milder form,
infantile Refsum disease (IRD [MIM 266510]), which
has predominant hepatic and gastrointestinal involve-
ment and more-prolonged survival (Baumgartner et al.
1998; Wanders 1999; Suzuki et al. 2001).
Retinitis pigmentosa (RP) and sensorineural deafness
are features common to all of the classic PBD phenotypes
but are also the hallmarks of the Usher syndromes (USH
[MIM 276900–276906, MIM 601067, MIM 602083,
MIM 602097, and MIM 605472]), a clinically and ge-
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netically heterogeneous group of disorders classified into
three distinct phenotypic subtypes, according to severity,
age at onset, and presence or absence of vestibulary dys-
function (Petit 2001). Here, we report the diagnosis of
a severe generalized PBD in an infant whose parents both
have RP associated with congenital sensorineural deaf-
ness. Both parents were originally diagnosed as having
USH but subsequently were shown to be suffering from
a PBD.
The index patient was the firstborn son of unrelated
parents (see below). He was born at term by Cesarean
section, because of breech presentation and oligohy-
dramnios. The Apgar score was 9 at 1 min and 10 at 5
min, birth weight was 2,720 g (3d percentile), and head
circumference was 33 cm (5th percentile). At birth, he
had a high-pitched cry, large anterior and posterior fon-
tanels, widely open sutures, low-set, narrow external au-
ditory canals, antimongoloid slanting of the eyes, hor-
izontal nystagmus, grade I subcapsular cataracts, a
webbed neck, widely spaced nipples, bilateral palmar
Simian lines, right undescended testis, extreme laxity of
the hips, and bilateral forefoot adduction. Karyotype
analysis was normal (46,XY).
At age 4 mo, he displayed little or no response to
visual and auditory stimuli, absence of smiling or social
contact, wandering nystagmus, marked axial hypoto-
nicity with dystonic limb hypertonicity, and hepatomeg-
aly. Additional dysmorphic features included huge fon-
tanels, dolichocephaly, high forehead, Brushfield spots,
anteverted nares, a long philtrum, narrow hard palate,
and mildly dysplastic auricles. By age 12 mo, he was
in a vegetative state, with opisthotonus, dystonia, myo-
clonic seizures, and a hypsarrhythmia pattern on elec-
troencephalography examination. Fundoscopy revealed
peripheral pigmentary changes consistent with RP, as
well as small optic disks. Electroretinography (ERG) ex-
amination revealed a flat response, and results of ex-
amination of visual evoked potential were compatible
with RP. Free-field audiometry documented bilateral sen-
sorineural deafness (left 55 dB, right 70 dB). Brain-stem
evoked-response–audiometry revealed delayed waves III
and V, with a hearing-level response (wave III) of 60 dB.
His subsequent course was characterized by severe feed-
ing difficulties necessitating nasogastric feeding, recur-
rent seizures, prolonged hospitalizations, and repeated
episodes of bronchopneumonia and respiratory failure
leading to death at age 17 mo.
The infant’s mother is of Jewish Algerian and Ash-
kenazi origin. Her parents were unrelated, and there is
no relevant family history. She was evaluated at age 3
mo, for cholestatic liver disease, which eventually re-
solved. She was noted to have strabismus and nystag-
mus, and RP was documented at age 12 mo. At age 24
mo, audiography performed because of speech delay re-
vealed severe bilateral sensorineural hearing loss (65 dB).
In view of the combination of RP and sensorineural deaf-
ness, she was diagnosed as suffering from USH. She uses
hearing aids, has night blindness and restriction of pe-
ripheral visual fields to 100, and exhibits a fine tremor
in both hands, and her IQ has been assessed as border-
line normal.
The infant’s father is of Yemenite Jewish origin. His
parents were first cousins. Three of his maternal first
cousins had RP and congenital deafness diagnosed as
USH. The father has severe congenital sensorineural
deafness (95 dB) that was presumed to be of infectious
origin. However, after the birth of his son, he underwent
ophthalmologic reevaluation and ERG examination,
which revealed mild RP, and he too was diagnosed as
having USH.
The diagnosis of a PBD in the infant was first suspected
at age 7 mo, when GC/MS examination of urine organic
acids revealed a distinctive dicarboxylic aciduria with re-
versal of the normal (C6 1 C8) ratio and prominence of
odd-chain-length dicarboxylic acids, 3-hydroxydicarbox-
ylic acids, 3,6-epoxydicarboxylic acids, and 2-hydroxy-
sebacic acid (Korman et al. 2000). This prompted ex-
amination of very-long-chain fatty acids (VLCFAs) in
plasma (table 1), which revealed a marked elevation of
both C26:0 and the C26:0/C22:0 ratio; in addition, there
was a significant elevation of the branched-chain fatty
acids (BCFAs)—phytanic acid and, particularly, pristanic
acid. Biochemical investigations of fibroblasts (table 1)
confirmed the elevation of VLCFAs and documented a
deficiency in the following multiple additional peroxi-
somal functions: (i) impaired de novo plasmalogen syn-
thesis (Schrakamp et al. 1988) and deficient dihydroxy-
acetonephosphate acyltransferase (DHAP-AT) activity
(Wanders et al. 1995c); (ii) deficient b-oxidation of
VLCFAs and pristanic acid (Wanders et al. 1995b); (iii)
deficient a-oxidation of phytanic acid (Wanders and Van
Roermund 1993); and (iv) abnormal immunoblot pat-
terns (Wanders et al. 1995a) for the peroxisomal enzyme
proteins acyl-CoA oxidase and peroxisomal thiolase. Fi-
nally, catalase-immunofluorescence analysis of fibroblasts
(Wanders et al. 1989) demonstrated the complete absence
of peroxisomes. Similarly, in liver-biopsy tissue (Espeel
and Van Limbergen 1995; Roels et al. 1995), no perox-
isomes were visible after staining for catalase activity,
whereas immunolocalization catalase and alanine-glyox-
ylate aminotransferase (AGT) revealed antigen in the cy-
toplasm of parenchymal cells and in some nuclei, but no
granules (fig. 1A and B). Absence of peroxisomes was
confirmed by electron microscopy; no organelles were la-
beled by catalase or AGT antibodies. However, weak im-
munogold labeling for the 70-kD peroxisomal membrane
protein was seen over rare and small vesicles of two types
that have been reported in the livers of some other patients
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Table 1
Biochemical Data on the Infant and His Parents
Measure Infant Mother Father Control Value
Plasma VLCFAs:
C22:0 (mg/ml) 8.6 21.1 18.0 10–35
C24:0/C22:0 ratio 1.30 .95 .90 .68  .15
C26:0/C22:0 ratio .303 .124 .054 .018  .009
Plasma branched-chain fatty acids (mg/ml):
Phytanic acid 4.1 4.8 4.5 .5–3.5
Pristanic acid 1.97 1.95 .62 .01–0.40
VLCFAs in fibroblasts:
C22:0 mmol/g protein 3.91 6.22 3.71 3.84–10.20
C24:0 mmol/g protein 9.83 13.00 11.93 7.76–17.66
C26:0 mmol/g protein 1.41 .48 .91 .18–.38
C24:0/C22:0 ratio 2.51 2.09 3.21 1.55–2.30
C26:0/C22:0 ratio .36 .08 .24 .03–.07
De novo plasmalogen synthesis in fibroblasts:a
pPE in PE (%) 14.4 59.0 39.0 64.5–85.7
pPC in PC (%) .8 1.6 1.1 2.0–8.0
3H/14C ratio in alkenyl PE 10.0 3.4 6.8 .3–2.4
3H/14C ratio in alkenyl PC 1.5 2.0 3.0 .3–2.0
DHAP-AT activity in fibroblasts:
DHAP-AT level (nmol/mg/2h) .8 7.4 5.6 10.9  2.5
DHAP-AT/GDH ratiob .3 3.2 2.2 6.6  2.2
Fatty-acid oxidation in fibroblasts:
C16:0 (palmitic) (pmol/h/mg) 1,999 3,078 3,151 2,841  681
C26:0 (cerotic) (pmol/h/mg) 229 1,131 824 1,937  440
Pristanic (pmol/h/mg) 9 287 167 1,126  267
Phytanic (pmol/h/mg) 8 22 23 68  29
a PE p ethanolamine glycerophospholipid; PC p choline glycerophospholipid.
b GDH p glutamate dehydrogenase.
with PBD (Espeel et al. 1995b): dense core organelles and
“empty” vesicles. Liver macrophages showed angulate ly-
sosomes containing stacks of trilamellar structures (fig.
1C), detected as birefringent inclusions in polarized light.
Macrophages also displayed small lipid droplets insoluble
in acetone.
This combination of clinical and laboratory findings
is diagnostic of a generalized PBD. All PBDs are auto-
somal recessively inherited, and obligate heterozygote
carriers do not display any clinical or biochemical fea-
tures (Moser et al. 1999); therefore, parents do not usu-
ally undergo biochemical investigations. In this case,
however, it was decided to investigate the parents, in
view of their auditory and visual handicaps. Surprisingly,
both parents were found to have elevated levels of
plasma VLCFAs and plasma BCFAs (table 1). Subse-
quent studies of fibroblasts confirmed that both parents
have a PBD, albeit in a mild form. VLCFA levels were
clearly elevated in the father’s fibroblasts but only mildly
so in the mother. Both had mildly deficient b-oxidation
of VLCFAs and pristanic acid, partially deficient a-ox-
idation of phytanic acid, abnormal de novo plasmalogen
synthesis, and mildly abnormal DHAP-AT activity. Re-
sults of thiolase immunoblotting were mildly abnormal
in the father but were normal in the mother.
This family is unique in that a patient with PBD was
born to parents who are themselves actually affected
by—rather than simply being asymptomatic carriers
of—a PBD. This fascinating observation indicates that
deficiency of multiple peroxisomal functions in both the
male partner and the female partner is not a barrier to
normal conception and reproductive function. Such a
union may be more common than a random occurrence,
given that (a) deafness is a major feature of PBD and
(b) there is a propensity for deaf individuals to marry
within their own community.
The fact that both parents in this family are clinically
and biochemically affected implies that they each must
have mutations in both alleles of a PEX gene, rather than
being heterozygous carriers of a single mutation. Fur-
thermore, for their offspring to be affected, it could be
deduced that both parents must be homozygous or com-
pound heterozygous for mutations in the same PEX gene.
This hypothesis was tested by complementation analysis,
whereby fibroblasts from two different patients are fused
to generate hybrid cells; restoration of function indicates
involvement of different complementation groups (CG),
reflecting mutations in different genes (Yajima et al.
1992). Using catalase immunofluorescence as the marker
of complementation in fused cells, the analysis revealed
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Figure 1 AGT immunolocalization and ultrastructure of liver. A, AGT immunolocalization in liver of index patient. Label is present in
cytoplasm and nuclei but not in granules. The same image is seen after staining for catalase (not shown). B, AGT immunolocalization in liver
of control. Peroxisomes (granules) are well visualized, and cytoplasm and nuclei are unstained (Scale bar p 10 mm). C, Ultrastructure of liver
of index patient, showing stacks of trilamellar inclusions in angulate lysosome of macrophage; drops of insoluble lipid are also shown. Both
inclusions are seen in all PBD livers (Scale bar p 0.1 mm).
that, indeed, the infant and his parents all belong to the
same complementation group, CG-C (equivalent to CG4
in the U.S. and European classifications).
PBDs belonging to CG-C (i.e., CG4) are caused by mu-
tations in the PEX6 gene [MIM 601498]. To determine
the dysfunction of PEX6 in both the infant and his par-
ents, we examined PEX6 cDNA from fibroblasts, by
means of RT-PCR; all mutations found were confirmed
at the gDNA level (table 2). As predicted by the comple-
mentation analysis, the infant and his parents were all
found to have mutations on both alleles of their PEX6
gene, confirming that the parents are truly affected by—
rather than only asymptomatic carriers for—a PBD. The
infant was compound heterozygous for a 1715CrTmu-
tation, leading to a T572I substitution at the protein
level, and a IVS102TrC splice-site mutation in intron
10, leading to aberrant splicing involving the retention
of intron 10, which probably does not lead to the syn-
thesis of a functional protein. The infant’s father is ho-
mozygous for the 1715CrT mutation, whereas the
infant’s mother is compound heterozygous for the
IVS102TrC splice-site mutation and two missense
mutations on the other allele (2426CrT and 2534TrC),
leading to two amino acid substitutions (A809V and
I845T, respectively). It is not clear whether both these
missense mutations are disease causing or whether one
of them represents a polymorphic variant. So far, neither
has been identified after analysis of 150 PEX6 alleles.
Analysis of the maternal grandparents’ DNA revealed
that the mother inherited the splice-site mutation from
her own mother and inherited the two missense muta-
tions, on her second allele, from her father.
Sixteen PEX6 mutations—including missense, non-
sense, frameshift, and splice-site mutations—have been
reported elsewhere (Fukuda et al. 1996; Yahraus et al.
1996; Zhang et al. 1999; Imamura et al. 2000; Matsu-
moto et al. 2001). Pex6p, the protein encoded by PEX6,
is a member of the AAA ATPase family and is involved
in the terminal steps of peroxisomal matrix–protein im-
port (Collins et al. 2000). PEX6-defective cells are thus
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Table 2
Primer Sets and Methods for PEX6 Mutation Analysis
Amplicon 5′ Primer (Forward) 3′ Primer (Reverse)
cDNA analysis:
Fragment 1 [21M13]-ACTAGTCGTCTGGTTCTCTG [M13rev]-GTGCCAGAAACCGCAAAGG
Fragment 1b [21M13]-TCCTCGTTGGTGTCCTGTC [M13rev]-GTGCCAGAAACCGCAAAGG
Fragment 2 [21M13]-CCAGACTGTGTCCAGAGTC [M13rev]-CACATAGAACATCCCCTTCC
Fragment 3 [21M13]-TGCCAGAGAGTTACACATCG [M13rev]-ATGGCCTGCAGTTTTGTCTC
Fragment 4 [21M13]-TGGGAAGACCACAGTAGTTG [M13rev]-TCCTCCTCAGTCAAGCCAC
Fragment 5 [21M13]-ACTTGGCACAGCTAGCACG [M13rev]-TCCATCACTCCTCCAGAATC
Fragment 6 [21M13]-AAAGTGAGGAGAATGTGCGG [M13rev]-TCTGTGGGCTATCAAGGTAC
gDNA analysis:
Exons 8 and 9 [21M13]-ACAAGGCAGTCCACAGGAG [M13rev]-CCACCCACCCATCTACATC
Exons 10 and 11 [21M13]-ATGGGACGCTGATGGTGAG [M13rev]-GAGCCGTCAGATGCACATAC
Exons 12 and 13 [21M13]-GTATGTGCATCTGACGGCTC [M13rev]-TCTCTGGACTCTGAAGACTG
Exons 14 and 15 [21M13]-TAAAGAGAGGTACCACAGGC [M13rev]-TGTTGCATGCATCCCCTAAG
NOTE.—Total RNA or genomic DNA was isolated from primary skin fibroblasts by the Wizard RNA purification kit
and the Wizard genomic DNA purification kit, respectively (Promega). For mutation analysis at the cDNA level, the
coding region of PEX6 cDNA was amplified by PCR in six overlapping fragments from first-strand cDNA prepared from
total RNA, as described elsewhere (IJlst et al. 1994), by use of the cDNA primer sets shown. For mutation analysis at
the genomic level, the complete exons plus flanking intron sequences from the PEX6 gene were amplified by PCR using
the gDNA primer sets shown. All forward and reverse primers used for mutation analysis were tagged with a 21M13
(5′-TGTAAAACGACGGCCAGT-3′) sequence and a M13rev (5′-CAGGAAACAGCTATGACC-3′) sequence, respectively.
PCR fragments were sequenced in two directions, by “21M13” and “M13rev” fluorescent primers, on an Applied
Biosystems 277A automated DNA sequencer, according to the manufacturer’s protocol (Perkin-Elmer).
deficient in the importation of peroxisomal matrix pro-
teins but retain some capacity for peroxisomal membrane
biogenesis. Accordingly, using antibodies against the 70-
kD peroxisomal membrane protein PMP70, we were able
to identify remnant peroxisomal membranous structures,
termed “ghosts,” in the infant’s liver and in fibroblasts
from the infant and from his parents (not shown).
A remarkable feature in this unique family is the strik-
ing disparity between the two affected generations, in se-
verity of both the clinical and the biochemical phenotypes.
Whereas the infant’s presentation was intermediate be-
tween the severe ZS and NALD phenotypes, the parents’
disease was even milder than the IRD phenotype. Such
milder variants have been reported elsewhere (Moser et
al. 1995; Baumgartner et al. 1998). Two observations
made in catalase-immunofluorescence–microscopy stud-
ies correlate with the parents’ milder phenotypes: mosa-
icism and temperature sensitivity (TS). In both parents’
fibroblasts, catalase-immunofluorescence microscopy re-
vealed a mosaic pattern, with peroxisomes present in
some cells and absent in others. Whether the parents have
a mosaic pattern also in hepatic tissue could not be de-
termined, since biopsy of the liver was not justified. The
fibroblasts and liver sample of the infant, who was more
severely affected, did not display peroxisomal mosaicism.
Mosaicism in livers of patients with PBD has been found
to be associated with a milder clinical course (Espeel et
al. 1995a; Giros et al. 1996; Pineda et al. 1999) and has
been described in patients belonging to CG4 and CG6,
which are associated with PEX6 mutations (Pineda et al.
1999, Matsumoto et al. 2001).
The second observation indicative of a milder pheno-
type is TS, the restoration of morphological peroxisome
formation and biochemical function in PBD fibroblasts
cultured at 30C, rather than at 37C. This has been dem-
onstrated only in fibroblasts with the milder NALD and
IRD phenotypes, but never in ZS cells. TS was evaluated
by determination of the percentage of immunofluorescent-
catalase–positive cells counted among 20 cells in each of
five fields at #1,000 magnification, after incubation of
fibroblasts for 72 h at either 37C or 30C (Imamura et
al. 1998). At 37C, peroxisomes were not detected at all
in fibroblasts from the infant or his mother and in only
7% of fibroblasts from his father; at 30C, however, per-
oxisomes were partially biosynthesized in the infant (37%
of fibroblasts), whereas peroxisomes were detected in
most of the cells from his mother (84% of fibroblasts)
and from his father (82% of fibroblasts). This finding of
TS in the parents’ fibroblasts is consistent with their rel-
atively mild clinical phenotype, whereas the partial TS in
the infant’s fibroblasts correlates with his clinical phe-
notype, which is intermediate between that of classic ZS
and classic IRD. In previous studies, TS has beendescribed
in a single PEX6 mutant (Imamura et al. 2000), as well
as in PEX1, PEX2, and PEX13 mutants; all TS mutants
identified thus far are missense mutations (Suzuki et al.
2001). The underlying basis for TS mutants has not been
definitely resolved but probably is related to a more ef-
fective folding process at lower temperature.
There is evidence to support the concept of phenotype-
genotype correlation for PBD caused by PEX1, PEX5,
PEX7, PEX10, and PEX12 defects (Moser 1999), and
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this correlation recently has been suggested for PEX6
also (Gootjes et al. 2001). From the clinical presentations
and corresponding genotypes in this family, it can be
inferred that the IVS102TrC allele has the most se-
vere—and that the A809VI845T allele has the least
severe—effect on the production and/or function of
Pex6p protein. This implies that, in the infant, the T572I
allele accounts for the partially temperature-sensitive
phenotype. The difference, in severity of phenotypes, be-
tween the parents and the offspring cannot be fully as-
sessed, however, until the functional consequences that
these mutations have for importation are determined by
expression studies in vitro (Zhang et al. 1999; Imamura
et al. 2000).
The differential diagnosis of sensorineural deafness as-
sociated with retinopathy includes USH, PBD, intrauter-
ine infections, perinatal complications, mitochondrial
respiratory-chain disorders, Alstrom syndrome, Senior-
Loken syndrome, and retinitis pigmentosa inversa with
deafness. Since USH is the most commonly identified
cause of combined deafness and blindness in developed
countries, it is understandable that the parents in this
study initially were labeled with this diagnosis. Deafness
may be the predominant and presenting feature of mild
varieties of PBD, and additional manifestations (such as,
in this family, RP or transient neonatal cholestasis) may
be subtle and easily missed. There is considerable overlap
between the clinical manifestations of USH and those of
milder PBD phenotypes. On the basis of both our own
experience and additional reports of patients with PBD
who have been misdiagnosed as having USH (Weleber
et al. 1984; Bader et al. 2000), we advocate that, in
patients with combined sensorineural deafness and RP
and suspected USH, PBD should be excluded, starting
with examination of plasma VLCFAs and BCFAs.
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